Switching on survival signalling to drive drug resistance

(Queen Mary University of London) Researchers at Queen Mary University of London have discovered that the loss of a single protein- PHLDA1- is sufficient for the development of drug resistance to a type of targeted therapy in endometrial and HER2-positive breast cancer cells.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news